Evaluating the Effects of Tasimelteon Vs. Placebo in Delayed Sleep-Wake Phase Disorder (DSWPD) and the CRY1Δ11 Variant
← catalyst calendarSponsored by Vanda Pharmaceuticals (industry) · VNDA — their whole pipeline →.
Phase
Phase 3
Status
Recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
60estimated
Sites
1
Country
Turkey (Türkiye)
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-10-08 | actual | When the study began enrolling |
| Primary completion | 2025-06-30 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-06-30 | estimated | The whole study's end, after follow-up |
| First posted | 2024-11-22 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2024-11-22 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Sleep Wake Disorders
- Sleep Disorders, Circadian Rhythm
- Chronobiology Disorders
- Gene Mutations and Other Alterations Nec
Interventions
- Drug: Tasimelteon
- Drug: Placebo
Primary outcome
what the primary-completion date above is the date OFLatency to Persistent Sleep, as measured by polysomnography.
measured Two Nights
Permalink · VNDA's whole pipeline · Catalyst calendar · Every registered study · What changed